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Abstract
In the central nervous system, cholinergic and dopaminergic (DA) neurons are among the cells most susceptible to the deleterious effects of age. 
Thus, the basal forebrain cholinergic system is known to undergo moderate neurodegenerative changes during normal aging as well as severe 
atrophy in Alzheimer’s disease (AD). Parkinson’s disease (PD), a degeneration of nigro-striatal DA neurons is the most conspicuous reflection of 
the vulnerability of DA neurons to age. In this context, cell reprogramming offers novel therapeutic possibilities for the treatment of these devastating 
diseases. In effect, the generation of induced pluripotent stem cells (iPSCs) from somatic cells demonstrated that adult mammalian cells can be 
reprogrammed to a pluripotent state by the overexpression of a few embryonic transcription factors (TF). This discovery fundamentally widened the 
research horizon in the fields of disease modeling and regenerative medicine. Although it is possible to re-differentiate iPSCs to specific somatic cell 
types, the tumorigenic potential of contaminating iPSCs that failed to differentiate, increases the risk for clinical application of somatic cells generated 
by this procedure. Therefore, reprogramming approaches that bypass the pluripotent stem cell state are being explored. A method called lineage 
reprogramming has been recently documented. It consists of the direct conversion of one adult cell type into another by transgenic expression of 
multiple lineage-specific TF or microRNAs. Another approach, termed direct reprogramming, features several advantages such as the use of universal 
TF system and the ability to generate a rejuvenated multipotent progenitor cell population, able to differentiate into specific cell types in response to a 
specific differentiation factors. These novel approaches offer a new promise for the treatment of pathologies associated with the loss of specific cell 
types as for instance, nigral DA neurons (in PD) or basal forebrain cholinergic neurons in the early stages of AD. The above topics are reviewed here.
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Regenerative Medicine and Cell Reprogramming
Introductory Remarks
The generation of induced pluripotent stem cells (iPSCs) from somatic cells 
has demonstrated that adult mammalian cells can be reprogrammed to a 
pluripotent state by the overexpression of a limited number of embryonic 
transcription factors (TF) [1]. The discovery of induced pluripotency represents 
the synthesis of scientific principles and technologies that have been developed 
over the last six decades. In 2006, Takahashi and Yamanaka demonstrated 
that the transfer of the four pluripotency genes Oct4, Sox2, cMyc and 
Klf4, to mouse fibroblasts can reprogram them, taking the cells to a stage 
in which they behave as embryonic stem cells (ESCs), which they termed 
iPSCs [1]. A year later, they demonstrated that the same genes, dubbed 
the Yamanaka genes, can reprogram human somatic cells to iPSCs [2].
These discoveries fundamentally changed the research in the fields of disease 
modeling and regenerative medicine, and have opened a horizon of hitherto 
unimagined possibilities for the development of personalized therapeutic 
strategies [3,4]. They offer a promising prospect for cell-based therapies 
aimed at repairing tissues or organs damaged by injury, degenerative 
disease, aging or cancer [5-7]. The potential advantage of using iPSCs 
is that pluripotent stem cells (SC) are able to differentiate into nearly all 
types of cells within the body [8], as had previously been shown for ESCs 
[9,10]. They are undifferentiated cells that can self-renew and proliferate to 
daughter undifferentiated cells as well as into mature specialized cells [11]. 
Cell reprogramming is an emerging technology that offers two major advantages 
over ESC-based therapeutic approaches. The first one is related to the fact that 
iPSCs can be generated from easily accessible somatic cells from the patient 
(skin fibroblasts, for instance). The iPSCs derived from the patient’s own 
cells will be autologous for her/him and therefore will not induce immunologic 
rejection when implanted. This is a necessary requirement for implementing 
genuine personalized regenerative medicine. The second advantage is of 
ethical nature and stems from the fact that the use of iPSCs does not require 
the destruction of embryos as is the case for conventional ESC therapy.
Although it is possible to re-differentiate iPSCs into specific differentiated 
cell types by culturing such iPSCs in media supplemented with appropriate 
factors, the procedure as a whole is costly, arduous and lengthy. Since the 
protocols to generate iPSCs include a number of stages, the efficiency with 
which the final cell type is generated can be low. Furthermore, a number 
of concerns about the safety and fidelity of iPSC-derived cells need to be 
addressed before these cells can be used clinically [12]. It is important to note 
that one of the most commonly used assays for demonstrating pluripotency is 
the capacity to forming teratomas [13]. Therefore, the tumorigenic potential of 
contaminating iPSC that failed to differentiate,  increases the risk for clinical 
application of somatic cells generated by this procedure [14]. Thus, other ways 
of reprogramming cells have been developed which involve direct conversion 
between cell types, thus avoiding passage through a pluripotency stage.
Transdifferentiation And Direct Reprogramming
Recently, a new cell reprogramming approach, known as lineage 
reprogramming or transdifferentiation, has emerged for the generation of 
specific cell types. It consists of the direct conversion of one adult cell 
type into another one by ectopic expression of multiple lineage-specific TF 
or microRNAs without the cell passing through the pluripotent SC state 
[15,16]. This strategy uses factors that show specific expression in target 
cells. Thus, the adenoviral-mediated gene transfer of a combination of 
three TF was reported to efficiently reprogram pancreatic exocrine cells into 
functional β cells in mice, which constituted the first documented evidence 
of cell reprogramming in vivo by defined factors [17]. Recent studies have 
demonstrated that direct lineage reprogramming can yield a diverse range 
of medically relevant cell types, such as cardiomyocytes and neurons [18-
20]. Table 1 summarizes a number of lineage reprogramming protocols 
that have been documented for the generation of induced neurons. 
The directly reprogrammed cells exhibit equivalent functionality to the 
cells differentiated from iPSCs or their in vivo counterparts and show no 
tumorigenicity when transplanted in vivo [21,22]. However, cells generated 
by this procedure may demonstrate restricted proliferative capacity, 
limited cell type diversity and even senescence [23], which may in turn 
substantially compromise their potential application in regenerative therapy.
Table 1.- Reprogramming Somatic Cells into Induced Neurons. DA: Dopaminergic; iNs: Induced Neuronal Cells.
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Cell type of origin Cell type induced strategy TFs used Reference
Embryonic stem cells Induced DA neurons Differentiation Hes5, Nurr1 and Pitx3 [35]
Mouse embryonic and postnatal 
fibroblasts
iNs Lineage reprogramming 
(transdifferentiation)
AscI1, Brn2, Myt1l [20]
Mouse tail tip fibroblasts Induced DA neurons Lineage reprogramming 
(transdifferentiation)
Acsl1, Mytl1, Brn2, Lmx1a, 
Lmx1b, Nurr1, Pitx3 and EN1
[19]
Human fibroblasts Induced DA neurons Lineage reprogramming 
(transdifferentiation)
Ascl1, Brn2 and Myt1l [36]
Fetal and postnatal human fibro-
blasts
iNs Lineage reprogramming 
(transdifferentiation)
Ascl1, Brn2, Myt1l and bHLH 
NeuroD1
[39]
Mouse and human fibroblasts Induced DA neurons Lineage reprogramming 
(transdifferentiation)
Ascl1, Nurr1 and Lmx1a [37]
Postnatal and adult human pri-
mary dermal fibroblasts
iNs Lineage reprogramming 
(transdifferentiation)
miR-124, Myt1l and Brn2 [40]
Hepatocytes iNs Lineage reprogramming 
(transdifferentiation)
Ascl1, Brn2 and Mytl1 [41]
Human fibroblasts DA neuron-like cells Lineage reprogramming 
(transdifferentiation)
Mash1, Ngn2, Sox2, nurr1 and 
Pitx3
[38]
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Another approach to regenerative medicine, termed direct reprogramming, 
is also emerging as an alternative to reprogramming via iPSC. The 
procedure uses fully differentiated somatic cells and converts them into other 
differentiated cell types, bypassing an intermediate pluripotent state. While 
in transdifferentiation, the conversion towards the cell lineage of interest 
is pushed by overexpression of lineage-specific factors, the pluripotency 
factor-mediated direct reprogramming (PDR) strategy [24] uses the same 
set of pluripotency factors as iPSC reprogramming, the Yamanaka genes, 
but they are expressed over a shorter period, usually 3 to 6 days. During 
this procedure, epigenetically unstable (EU) intermediate cells, which are 
responsive to differentiation factors, are generated. This new method has 
several advantages such as the use of a universal pluripotency gene 
system and the ability to generate a rejuvenated multipotent progenitor cell 
population, able to differentiate into various tissue-specific destination cells 
under specific conditions [24-26]. Table 2 lists specific reports of PDR.
Conventional lineage reprogramming and direct reprogramming share in 
common a direct conversion from one cellular type to another and are patient-
specific. Both approaches avoid passing through an intermediate pluripotent 
stage, relying on specific signals to help the original cells reach the desired cell-
type destination. In contrast to lengthy iPSC-mediated cell type conversion, in 
the direct approaches the conversion usually occurs in a short period of time.
The Promise of Cell Reprogramming for the Aging Brain
Brain Aging
Aging is associated with a progressive increase in the incidence of 
neurodegenerative diseases in both laboratory animals and humans. In the 
central nervous system (CNS), cholinergic and dopaminergic (DA) neurons 
are amongst the cells most susceptible to the deleterious effects of age and 
environmental insults. Thus, the basal forebrain cholinergic system is known 
to undergo moderate neurodegenerative changes during normal aging as 
well as severe atrophy in Alzheimer´s Disease (AD). In fact, the cholinergic 
degeneration in AD seems to occur against a background of age-related 
atrophy and the exacerbated atrophy in AD can be detected at very early stages 
of cognitive impairment [27]. In rats, aging is associated with degenerative 
and/or atrophic changes in the forebrain cholinergic system and these 
morphologic changes are paralleled by a decline in spatial learning ability [28].
 
Parkinson’s disease (PD) is a neurological disorder characterized by the 
degeneration and progressive loss of DA neurons in the midbrain substantia 
nigra, leading to a reduction of dopamine in the striatum [29]. PD affects 
0.1-0.3% of the population and is the most conspicuous reflection of the 
vulnerability of DA neurons to age. In rats, aging brings about a progressive 
degeneration and loss of another group of central DA neurons namely, 
the hypothalamic tuberoinfundibular dopaminergic (TIDA) neurons, which 
are involved in the tonic inhibitory control of prolactin secretion and 
lactotropic cell proliferation in the adenohypophysis [30]. Progressive 
dysfunction and loss of TIDA neurons during normal aging is associated in 
the female rat, with chronic hyperprolactinemia [31] and the development 
of pituitary prolactinomas [32]. Although aging rats do not develop 
parkinsonian symptoms, even at 32 months of age, they lose 35-40% 
nigral DA neurons and show a marked decline in motor performance [33].
In humans, normal aging is also associated with a decline in motor performance 
and a progressive loss of nigral DA neurons [34]. Therefore, progressive 
decline in cognitive function and central DA activity seems to represent 
basic features of normal aging both in humans and laboratory rodents. 
Exacerbation of these processes would lead to AD and PD, respectively. 
In this context, SC therapy and cell reprogramming emerge as powerful 
technologies that promise to make it possible implementing personalized 
regenerative medicine aimed at preventing or delaying the progress of AD and 
PD. There is also a growing interest in the use of neural stem cells (NSCs) 
engineered to express oncolytic genes, for the treatment of brain tumors but 
the topic is beyond the scope of this article and will not be reviewed here. 
Reprogramming Somatic Cells to Induced Neurons
There is a keen interest in obtaining mature neurons and neural precursors 
from somatic cells (e.g., fibroblasts) by transdifferentiation and direct 
reprogramming, which can later be used for implementing cell therapy for 
neurodegenerative pathologies like AD and PD. It has been demonstrated that 
non-neural human somatic cells, as well as pluripotent SC, can be directly 
converted into neurons by lineage-determining TF. Currently, DA neurons can 
be obtained through differentiation from ESCs [35] and by direct conversion 
from fibroblasts [19,36-38]. It was initially shown that mouse embryonic 
and postnatal fibroblasts can be efficiently converted into functional neurons 
in vitro by transfer of the genes for only three neuronal lineage-specific TF 
namely, Ascl1, Brn2 and Myt1l [20]. The induced neuronal cells (iNs) express 
multiple neuron-specific proteins, generate action potentials and form 
functional synapses. When they are combined with the basic helix-loop-helix 
NeuroD1 factor, these three TF could also convert human fibroblasts into iNs 
that display typical neural morphologies and express multiple neural markers 
[39]. These human iNs are able to generate action potentials and to receive 
synaptic contacts with mouse cortical neurons in co-culture. Subsequently, 
it was reported that a combination of the TF Ascl1, Nurr1 and Lmx1a
was able to generate functional DA neurons from mouse and human fibroblasts 
without reverting to a progenitor cell stage [37]. This study also showed that 
DA neurons can be generated from cells of patients with PD. The combination 
of a microRNA (miR-124) and two TF (Myt1l and Brn2) is sufficient to directly 
reprogram postnatal and adult human primary dermal fibroblasts to functional 
neurons under precisely defined conditions [40]. These human iNs exhibit 
typical neural morphology and marker gene expression, fire action potentials 
and produce functional synapses between each other. These findings clearly 
show that the overexpression of a few ‘master’ factors is sufficient to drive 
relatively rapid and direct specific lineage changes in cells derived from 
different embryonic layers. In effect, lineage conversion is not restricted to 
within the same lineage or germ layer, since mesodermal source fibroblasts 
give rise to neurons, which are cells derived from the ectoderm. Additionally, 
it was demonstrated that terminally differentiated hepatocytes derived from 
the endoderm can be converted into iNs by overexpression of Ascl1, Brn2 
and Mytl1 [41]. Additional studies have demonstrated that expression of 
subtype-specific regulatory factors in mouse and human fibroblasts results in 
the establishment of specific neuronal subtypes, like DA neurons [36-38].
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Generation of Induced Neural Stem Cells and Neural 
Progenitor Cells from Fibroblasts
Generation of iNs from non-neural lineages could have important implications 
for studies of neural development and neurological disease modeling because 
transdifferentiated neurons can be obtained from patients. Furthermore, they 
can be also used for producing neurons for regenerative medicine. However, 
terminally differentiated iNs are not adequate for transplantation [42] because, 
due to their limited ability to proliferate, only few cells usually survive and 
become functionally integrated to the brain [43]. Therefore, the treatment 
effectiveness of iNs transplantation is not optimal. Because differentiated 
cells are post-mitotic and non-dividing, the process of generating sufficient 
numbers of cells for further basic and clinical applications constitutes a 
significant challenge. Progenitors and precursors should be advantageous in 
handling and obtaining the cells in vitro as well as for proper integration in vivo. 
In order to overcome the above hurdles, various studies have focused on 
the generation of induced NSCs (iNSCs) and neural progenitor cells (NPCs) 
from fibroblasts [25, 44-49]. These cells can differentiate into neurons and 
glial cells, the two major cell types in the CNS [50]. While NSCs are self-
renewing cells capable of producing neurons, astrocytes and oligodendrocytes 
[51], NPCs have limited self-renewal capacity. There are two main strategies 
to reprogram fibroblasts to iNSCs or NPCs: a direct method and an indirect 
method (PDR) that involves an intermediate destabilized state (see above). 
Table 2.- Generation of Induced Neural -Stem Cells and -Progenitor Cells from Fibroblasts. NSCs:  neural stem cells, NPCs: neural progenitor cells
Table 2 lists several reports using PDR or lineage reprogramming to obtain 
iNSCs and iNPCs. The PDR strategy was initially used by Kim et al. [25] 
who showed that transient induction of the four pluripotency factors (Oct4, 
Sox2, Klf4 and c-Myc) under the control of a DOX-inducible promoter 
for 3-6 days, followed by appropriate signaling inputs, can efficiently 
transdifferentiate fibroblasts into functional iNSC/NPCs. The fact that a 
number of studies have indicated that iPSCs are generated in a sequential 
and stochastic manner [52-54], led Kim et al. to hypothesize that they could 
be able to manipulate cells at an early and epigenetically highly unstable state 
induced by the Yamanaka reprogramming factors. Different conditions could 
potentially give rise to a multitude of cell types with more stable epigenetic 
profiles [55]. When such EU mouse fibroblasts are grown in a medium that 
contains the neurogenic molecules, fibroblast growth factor 2 (FGF2), FGF4 
and epidermal growth factor (EGF), colonies of cells showing many of the 
features of NPCs are generated after 8-9 days in culture. This process is 
highly specific and efficient, requiring only a single step that is completed 
within 13 days, yielding almost 100% newly generated colonies that were 
mostly composed of NPCs [25]. Compared with iNs, NPCs have the distinct 
advantage of being expandable in vitro and retaining the ability to give rise to 
multiple neuronal subtypes and glial cells. Another advantage of this method 
is the use of general reprogramming TF instead of lineage-specific TF.
Cell type of origin Cell type induced Strategy TFs used Reference
Mouse fibroblasts  NSC/NPCs Direct reprogram-
ming strategy 
(PDR)
Oct4, Sox2,
Klf4, c-Myc 
[25]
Mouse fibroblasts NSCs PDR Sox2, Klf4 and 
c-Myc
[48]
Mouse and human fibroblasts NSCs PDR Sox2 [45]
Mouse embryonic fibroblasts Bipotent NPC/tripotent 
NPC/NPC-like cells
Lineage reprogram-
ming (transdifferen-
tiation)
Sox2 and FoxG1/
Sox2, FoxG1 and 
Brn2/FoxG1 and 
Brn2
[56]
Mouse fibroblasts NSCs Lineage reprogram-
ming (transdifferen-
tiation)
Sox2, c-Myc, Klf4 
and Brn4
[57]
Thier et al. [48] showed that constitutively inducing Sox2, Klf4 and c-Myc 
while strictly limiting Oct4 activity to the initial 5-day phase of reprogramming, 
generated iNSCs. These iNSCs that could be expanded for more than 50 
passages, uniformly displayed morphological and molecular features of 
brain-derived NSCs and had a genome-wide transcriptional profile similar 
to them. Thus, self-renewable and multipotent iNSCs devoid of tumorigenic 
potential, can be generated directly from fibroblasts by restricted pluripotency 
gene overexpression. The generation of iNSCs from mouse and human 
fibroblasts by direct reprogramming with a single factor, Sox2, was also 
reported [45]. These iNSCs express NSC markers and resemble wild-type 
NSCs in their morphology, self-renewal ability to form neurospheres and 
gene expression profiles. They can differentiate into several types of mature 
neurons indicating multipotency. Implanted iNSCs can survive and integrate 
in mouse brains and, unlike iPSC-derived NSCs, they do not generate 
tumors. These iNSCs showed an extensive self-renewal capacity compared 
with the limited passaging ability of the iNSC/NPCs generated by Kim et al. 
[25], which could be expanded for only a few passages, thus excluding the 
possibility that the cells have a permanent self-renewing capacity, a critical 
requirement for clinical applicability. Besides, the cells obtained by Kim et al. 
apparently lacked the potential to differentiate into oligodendrocytes. 
While it has been shown that defined sets of TF are sufficient to convert 
fibroblasts directly into iNs, for some applications it would be desirable to 
convert fibroblasts into proliferative NPCs instead of neurons. Lujan et al. 
[56] demonstrated that it is possible to obtain NPCs using the same main 
approach used for generating iNs, which is a strategy different from that 
of Kim et al. Towards this goal, the approach started with a set of 11 
candidate genes for TF highly expressed in NPCs which were transferred to 
mouse embryonic fibroblasts by means of retroviral vectors. Using stepwise 
elimination, they found that Sox2 and FoxG1 are capable of generating 
clonal self-renewing, bipotent induced NPCs that gave rise to astrocytes and 
functional neurons. When the gene for Brn2 was added, tripotent NPCs were 
generated which could be differentiated not only into neurons and astrocytes 
but also into oligodendrocytes. Furthermore, FoxG1 and Brn2 alone were also 
capable of inducing NPC-like cells, which generated less mature neurons, 
although they did produce astrocytes and even oligodendrocytes capable of 
integration into dysmyelinated Shiverer mouse brains.
In a similar reprogramming strategy for the direct reprogramming of 
fibroblasts into iNSCs, Han et al. [57] started with the above list of 11 
candidate genes for TF, three SC factors, Sox2, Klf4, and c-Myc, together 
with eight neural specific TF. They then tested different combinations and 
by systematic elimination, the list of effective factors was reduced to a 
smaller number in the reprogramming cocktail. They showed that Sox2, 
c-Myc, Klf4 and Brn4 were active factors sufficient to induce direct 
transdifferentiation of mouse fibroblasts into iNSCs, in what was a gradual 
process in which the fibroblast transcriptional program was silenced over 
time. These iNSCs exhibit cell morphology, gene expression, epigenetic 
features, differentiation potential and self-renewal capacity, as well 
as in vitro and in vivo functionality similar to that of wild-type NSCs.
The clinical applications of iNSCs and NPCs are significantly compromised by 
the fact that the reprogramming strategy to generate them involved integrative 
gene transfer with the well-known risk of insertional mutagenesis or gene 
silencing. We hypothesize that adenoviral vectors offer a safer reprogramming 
alternative and have thus, designed a regulatable helper-dependent (HD) 
adenovector expressing the four pluripotency genes Oct4, Sox2, Klf4 and 
c-Myc, as well as the humanized green fluorescent protein (hGFP) gene 
which should allow us to implement the strategy of Kim et al. [25] in a non 
integrative fashion (Figure. 1). In order to overcome the lower transduction 
efficiency of adenoviral as compared to retroviral vectors, we plan to use 
the magnetofection technique during cell reprogramming. Magnetofection is 
based on complexing adenovectors to magnetic nanoparticles which under 
the influence of a magnetic field, efficiently enter the target cells. This 
procedure markedly increased transduction efficiency of HD-adenovectors in 
cell culture and in vivo [58]. Using the adenovector shown in (Figure. 1) and 
the magnetofection technique, we plan to implement a direct reprogramming 
protocol on mouse and human fibroblasts in which the four Yamanaka 
pluripotency genes will be expressed for a short time (4 days) in order to 
obtain EU fibroblasts which are responsive to a variety of differentiation 
factors. These EU fibroblasts will then be exposed to suitable neurogenic 
factors in order to induce NPCs and terminally differentiated neurons.
Figure 1. Diagrammatic Representation of  the Genome of an  Hd-Adenovector Suitable for Non Integrative Cell Reprogramming. 
Under basal conditions the vector expresses the four Yamanaka genes and the gene for hGFP. Expression of pluripotency genes and hGFP can be readily 
inhibited by doxycycline addition to the culture medium. TRE, tetracycline-responsive element; PminCMV, human cytomegalovirus minimal promoter; PCMV, CMV 
full promoter; tTA, tetracycline-responsive transcriptional activator; hGFP, Reporter cDNA; SV40pA, simian virus 40 polyadenylation signal; ψ, packaging signal; 
ITR, inverted terminal repeats; P2A, F2A, CHYSEL self-processing sequences; IRES, internal ribosome entry site; hOct4, hKlf4, hSox2, hcMyc, Yamanaka 
pluripotency genes.
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The Potential of Cell Reprogramming for the Treatment of PD 
and AD
The absence of efficacious therapies for neurological disorders has increased 
the interest in regenerative medicine based on cellular approaches, 
particularly SC technology. Stem cell therapy has been attempted in animal 
models and also in some clinical trials for neurodegenerative diseases, such 
as PD, AD, multiple sclerosis and amyotrophic lateral sclerosis [59-65] 
as well as in ischemic brain and spinal cord traumatic lesions [66, 44]. 
Different kinds of SC have been used for the treatment of neurological 
diseases [67] and, although the results of transplantation in animal models 
were encouraging, human clinical trials have not produced the same results.
Therapeutic Potential of Cell Reprogramming for PD
The use of ESCs as a source of DA neurons for the treatment of PD is a 
topic of growing interest and there is evidence that DA neurons derived from 
mouse ESCs survive for extended periods (over 37 weeks) in rodent models 
of PD [68]. Furthermore, mouse ESCs can spontaneously differentiate into 
DA neurons when implanted in the striatum of rats whose nigral DA neurons 
have been pharmacologically lesioned [69]. The newly generated DA 
neurons cause a gradual and sustained behavioral reversion of DA-mediated 
motor asymmetry. Like ESCs, iPSCs can be induced to differentiate into DA 
neurons and can be subsequently implanted into the brain of rat models of 
PD where they are able to improve behavior [63]. The possibility to induce 
NSCs from human  somatic cells, e.g. fibroblasts, has opened new horizons 
for research in human disease modeling and cellular therapeutic applications 
in the neurological field. Cell reprogramming offers a major advantage over 
ESC-based therapeutic approaches for PD and AD. In effect, iPSCs as 
well as iNSCs and NPCs can be derived from easily accessible somatic 
cells from the patient (skin fibroblasts, for instance). The use of iNSCs 
may overcome some of the drawbacks of SC therapy. The fact that iNSCs 
can be expanded in vitro for a potentially unlimited number of passages, 
which is not the case of iNs, constitutes a convenient feature as clinical 
applications involving SC transplantation usually require large amounts of 
donor cells. As mentioned above, the induced neurons derived from the 
patient’s own cells will be autologous for him/her and therefore will not 
induce immunologic rejection when implanted. This could reduce rejection 
problems that manifest during use of ESCs or other SC derived from different 
donors. Given that iNSCs are committed towards neural lineage, they are 
able to generate the three major neural cell types [45], enabling them 
to be adaptable with a lower risk of neoplastic formation [14,70,71]. In 
contrast, ESCs such as iPSCs are able to differentiate into a wide range of 
cell types, showing high plasticity and manifesting tumorigenic potential in 
transplanted animals [14,72]. Thus, iNSCs can differentiate into the same 
type of cells of their immediate environment, while still maintaining the ability 
to replicate after transplantation [46, 73], which is important for treating 
pathologies that are induced by both degeneration of brain parenchyma 
and deregulation of inflammatory cells, requiring replacement of both 
components [44, 74]. It will also be of interest to explore the possibility 
of inducing transdifferentiation directly in the tissue for regeneration and 
repair in situ. In this way, it may be possible to use iNSCs to develop 
new advanced therapeutic approaches for neurodegenerative disorders.
However, there is evidence that NSC are more likely to differentiate into 
glial cells than into functional neurons after transplantation [75, 76], which 
is a disadvantage for neuron-replacement therapy of neurodegenerative 
diseases. As the PDR approach can generate proliferating iNSCs under 
appropriate environmental conditions, DA progenitors (DAP) also can be 
generated under appropriately modified environment conditions by the 
same strategy. Although these DAP are more committed than general 
NSCs they are not terminally differentiated neurons. Recently, Kim et 
al. [77] showed that mouse fibroblasts can be directly reprogrammed 
into midbrain-specific DAP through the transient expression of the four 
Yamanaka genes under DA neuron-specific and intermediate cell-enriching 
conditions. This study demonstrates the feasibility of inducing a direct 
cell fate alteration from fibroblast to specific neural progenitors through 
a PDR strategy and provides another novel route for obtaining useful 
progenitors for potential therapies and studies on various neural diseases.
Therapeutic Potential of Cell Reprogramming for AD
The initial stages of AD are characterized by an early substantial loss of basal 
forebrain cholinergic neurons (BFCN) which leads to deficits in spatial learning 
and memory. Consequently, cholinergic neuron replacement constitutes a 
relevant therapeutic goal and, interestingly, it has been recently shown that 
BFCN can be consistently derived from human ESCs [78]. It has been also 
demonstrated that functional neurons can be generated by reprogramming 
skin fibroblasts from normal individuals and familiar AD patients [79].
Neural restricted progenitors (NRPs), also known as neuroblasts, represent 
a type of transitional intermediate cells that lie between multipotent NPCs 
and terminally differentiated neurons during neurogenesis. These NRPs 
have the ability of self-renewal and migration in the nervous system [80, 
81]. They can differentiate into neurons rather than glial cells in vivo and 
in vitro [82, 83], which constitutes an important advantage for cellular 
therapy of human neurodegenerative diseases. When injected into the 
subventricular zone, NRPs can migrate extensively and integrate into 
different regions of the brain, to then differentiate into various subtypes 
of neurons, contributing to brain plasticity and repair [81]. Unfortunately, it 
is difficult to obtain highly purified NRPs from normal nervous tissue [80, 
84], which prevents further studies and applications that require relatively 
large number of cells. Recently, it was demonstrated that by using only 
three defined factors, Sox2, c-Myc and either Brn2 or Brn4, human fetal 
fibroblasts can be converted to human induced NRPs (hiNRPs) [85]. 
These hiNRPs exhibit distinct neuronal characteristics including a capacity 
for self-renewal, expression of multiple neuronal markers, neuron-like 
morphology and a neuronal genome-wide transcriptional profile. They could 
be differentiated into various terminal neurons with functional membrane 
properties, but not into glial cells. Thus, the direct conversion of hiNRPs 
from somatic cells with a high efficiency may provide a new source of cells 
for neuronal development studies as well as for cellular replacement therapy 
of human degenerative diseases, such as PD, AD and Huntington’s chorea.
Enliven Archive | www.enlivenarchive.org 6 2014 | Volume 1 | Issue 1 
Enliven Archive | www.enlivenarchive.org 7 2014 | Volume 1 | Issue 1 
Concluding Remarks
The increase of the elderly population is an almost worldwide phenomenon. 
Consequently, the incidence of age-related neurological (and other) 
pathologies like PD and AD is becoming a problem of significant medical and 
economic impact which is further exacerbated by exposure of the general 
population to increasing levels of environmental pollutants. In this context, 
research and development of novel therapeutic approaches and molecular 
tools like regenerative medicine and regulatable polycistronic non integrative 
vectors expressing suitable TF respectively, may open new avenues for the 
treatment of these devastating neurological pathologies. In recent years, 
cell reprogramming has emerged as a powerful technology that promises 
to make it possible to implement personalized regenerative medicine for 
neurodegenerative diseases. It seems therefore plausible to hypothesize that 
in the not-too-distant future a mature cell reprogramming technology will 
provide effective means for curing and functionally restoring the aging brain.
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